PE-22-28
Also known as: Spadin Analog
A peptide targeting TREK-1 channels for antidepressant effects.
Overview
PE-22-28 is a synthetic peptide derived from sortilin propeptide that blocks TREK-1 potassium channels. This mechanism provides rapid antidepressant effects without typical side effects.
Mechanism of Action
Blocks TREK-1 potassium channels, which are involved in serotonergic neurotransmission. Rapidly increases hippocampal neurogenesis and provides antidepressant effects.
Pharmacokinetics
Can be administered peripherally with CNS effects. Mechanism of brain penetration under investigation.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research
100-300 mcg
Once daily
2-4 weeks
Based on animal model extrapolation
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Rapid antidepressant effects in animal models (within days)
- 2Increased hippocampal neurogenesis
- 3No sedation or cognitive impairment
- 4Novel mechanism distinct from SSRIs
Side Effects & Contraindications
Reported Side Effects
- Limited data
Contraindications
- Unknown
Safety Considerations
Limited human safety data. Preclinical studies suggest good tolerability.
Storage Requirements
Store at -20C
Scientific References
- 1